文献速递胃肠动力与功能性疾病

大麻素与胃肠道

Cannabinoids and the Gastrointestinal Tract.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-09-09

本文综述内源性大麻素合成降解、大麻素受体分布及其对消化器官免疫炎症、神经肌肉和感觉功能的作用机制。CB2机制在免疫和感觉功能中尤为重要。大麻素通常抑制胃肠动力,但可缓解胃轻瘫和多种恶心综合征症状。大麻素对炎症机制的作用在相对较小的安慰剂对照研究中显示有望降低炎症性肠病疾病活动度和腹痛。大麻二酚在胃轻瘫患者4周治疗中降低胃轻瘫主要症状指数总评分并提高进食耐受能力,而对胃排空正常的功能性消化不良主要疼痛终点未显著改善。CB2激动剂奥洛那班在开放标签试验中降低炎症性肠病腹痛,在安慰剂对照试验中降低便秘型肠易激综合征腹痛。结论认为大麻素尤其影响CB2机制的药物在炎症、胃轻瘫和疼痛障碍中有潜力,但试验需重复及进一步理解风险获益以促进大麻素在胃肠疾病中的应用。

要点

  • CB2机制在免疫和感觉功能中尤为重要
  • 大麻素通常抑制胃肠动力,但可缓解胃轻瘫和恶心综合征症状
  • 大麻二酚在胃轻瘫4周治疗中降低胃轻瘫主要症状指数总评分并提高进食耐受能力

核心结论

  • 大麻素尤其影响CB2机制的药物在炎症、胃轻瘫和疼痛障碍中有潜力,但试验需重复及进一步理解风险获益以促进大麻素在胃肠疾病中的应用。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 大麻素通常抑制胃肠动力,但可缓解胃轻瘫和多种恶心综合征症状。
  • 大麻二酚在胃轻瘫患者4周治疗中降低胃轻瘫主要症状指数总评分并提高进食耐受能力。
  • 大麻二酚对胃排空正常的功能性消化不良主要疼痛终点未显著改善。
  • CB2激动剂奥洛那班在开放标签试验中降低炎症性肠病腹痛,在安慰剂对照试验中降低便秘型肠易激综合征腹痛。
  • 大麻素对炎症机制的作用在相对较小的安慰剂对照研究中显示有望降低炎症性肠病疾病活动度和腹痛。

关键数值与推荐

  • 大麻二酚在胃轻瘫患者4周治疗中降低胃轻瘫主要症状指数总评分并提高进食耐受能力。
  • 大麻二酚对胃排空正常的功能性消化不良主要疼痛终点未显著改善。
  • CB2激动剂奥洛那班在开放标签试验中降低炎症性肠病腹痛,在安慰剂对照试验中降低便秘型肠易激综合征腹痛。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 大麻素对炎症机制的作用在相对较小的安慰剂对照研究中显示有望降低炎症性肠病疾病活动度和腹痛。
  • 试验需重复及进一步理解风险获益以促进大麻素在胃肠疾病中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The synthesis and degradation of endocannabinoids, location of cannabinoid (CB) receptors, and cannabinoid mechanisms of action on immune/inflammatory, neuromuscular, and sensory functions in digestive organs are well documented. CB2 mechanisms are particularly relevant in immune and sensory functions. Increasing use of cannabinoids in the United States is impacted by social determinants of health including racial discrimination, which is associated with tobacco and cannabis co-use, and combined use disorders. Several conditions associated with emesis are related to cannabinoid use, including cannabinoid hyperemesis or withdrawal, cyclic vomiting syndrome, and nausea and vomiting of pregnancy. Cannabinoids generally inhibit gastrointestinal motor function; yet they relieve symptoms in patients with gastroparesis and diverse nausea syndromes. Cannabinoid effects on inflammatory mechanisms have shown promise in relatively small placebo-controlled studies in reducing disease activity and abdominal pain in patients with inflammatory bowel disease. Cannabinoids have been studied in disorders of motility, pain, and disorders of gut-brain interaction. The CB2-receptor agonist, cannabidiol, reduced the total Gastroparesis Cardinal Symptom Index and increases the ability to tolerate a meal in patients with gastroparesis appraised over 4 weeks of treatment. In contrast, predominant-pain end points in functional dyspepsia with normal gastric emptying were not improved significantly with cannabidiol. The CB2 agonist, olorinab, reduced abdominal pain in inflammatory bowel disease in an open-label trial and in constipation-predominant irritable bowel syndrome in a placebo-controlled trial. Cannabinoid mechanisms alter inflammation in pancreatic and liver diseases. In conclusion, cannabinoids, particularly agents affecting CB2 mechanisms, have potential for inflammatory, gastroparesis, and pain disorders; however, the trials require replication and further understanding of risk-benefit to enhance use of cannabinoids in gastrointestinal diseases.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Camilleri M, Zheng T. Cannabinoids and the Gastrointestinal Tract. Clin Gastroenterol Hepatol. 2023. PMID: 37678488. doi:10.1016/j.cgh.2023.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。